In short
Podcast Notes: CNBC's "Fast Money" - Tech Helps Fuel Market Rally… And Sarepta Therapeutics’ Plummets (6/16/25)
Episode Overview
- Hosts: Melissa Lee and a roundtable of top traders.
- Key Topics:
- Market rally driven by tech stocks amidst geopolitical concerns.
- Significant drop in shares of Sarepta Therapeutics.
- The impact of the Israel-Iran conflict on market sentiments.
Market Context
- Market Performance:
- Stocks opened the week positively despite escalating tensions in the Middle East.
- The Dow rose over 300 points, S&P up nearly 1%, and Nasdaq leading gains at 1.5%.
- Notable performances from MAG7 stocks alongside legacy tech companies (IBM, Microsoft at all-time highs).
Major Discussions
Tech Sector Highlights
- MAG7 vs. Legacy Tech:
- The MAG7 stocks (including heavyweights like Apple, Amazon) are seen as potential market leaders.
- Legacy tech (IBM, Microsoft) exhibiting strength, with IBM surprising analysts due to its valuation and business focus on quantum computing.
- AI Reignition:
- The AI trade is back, bolstered by NVIDIA's partnerships and reaffirmation of tech demand.
- Positive sentiment is driving tech stock performances, leading to all-time highs across various tech ETFs.
Sarepta Therapeutics
- Stock Performance:
- Shares plummeted by over 40% after a reported death related to its Duchenne muscular dystrophy gene therapy.
- Company suspends shipments of the therapy to non-ambulatory patients.
- Market Reaction:
- Analysts express concern over the implications for the ambulatory patient group.
- Valuation estimates vary significantly, with some suggesting a price range of $30-$40 per share post-event.
Broader Economic Insights
- Geopolitical Tensions:
- Investors appear to be ignoring geopolitical risks as long as oil prices remain stable.
- The market shows resilience, suggesting a focus on domestic economic indicators rather than international conflicts.
- Consumer Dynamics:
- Discussion on discount retailers gaining momentum due to market consolidation, with notable mentions of Dollar Tree and Dollar General.
- Implications of inflation and consumer spending habits are highlighted as ongoing concerns for companies like Target.
Key Takeaways
- Bullish Sentiment:
- Market optimism is primarily driven by tech stocks, especially in AI.
- Institutional investors are rotating into high-quality stocks amidst concerns over interest rates and potential recession risks.
- Investment Strategies:
- Analysts recommend focusing on quality stocks, particularly within the tech sector, while being cautious about valuations.
- The biotech space remains volatile, with Sarepta's situation underscoring the sector's risk-reward profile.
- Looking Ahead:
- The upcoming G7 talks and trade agreements may influence market direction.
- Ongoing monitoring of geopolitical developments and their economic impacts is essential.
Final Remarks
- Market Analysis: The episode illustrates a blend of optimism driven by tech performance and caution stemming from geopolitical uncertainties and individual stock volatility (notably in biotech).
- Next Steps: Investors are advised to stay informed on both macroeconomic indicators and individual stock performances, particularly in the tech and biotech sectors.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Transcript
Automatic transcript. May contain errors.0:00You're listening to Fast Money in Progress.
0:31What do you say? Mr. President, Iran is actually saying Netanyahu of attacking them to deliberately derail your nuclear plan that you had. What do you say to that? Do you think that's true? No, no. Look, Iran should have signed the deal. If it would help bring Iran to the negotiating table, would you guarantee that the U.S. would not get involved militarily? Well, I think this. I think Iran basically is at the negotiating table. They want to make a deal. And as soon as I leave here, we're going to be doing something. But I have to leave here. I have this commitment. have a lot of commitments, have a commitment to a lot of countries, including the U.K., where we just signed our deal.
1:08Mr. President, when will we... The Press. The Press. We're going to let you have that information in a little while. The Press. When will they restart? The Press. They're starting already. Mr. President, do you want to wait to apply more sanctions on Russia? Well, Europe is saying that, but they haven't done it yet. Let's see them do it first. You told me earlier that you could sanction Russia. Why wait? Why wait to sanction them? Because I'm waiting to see whether or not a deal is signed. Can you guarantee the UK won't be subject to any people? And don't forget, you know, sanctions cost us a lot of money.
1:50When I sanction a country, that costs the US a lot of money, a tremendous amount of money. It's not just, let's sign a document. You're talking about billions and billions of dollars. The sanctions are not that easy. It's not just a one-way street. And just quickly, do you think that Israel can... Is that still proceeding? You think it's a sort of review of that? Yeah, we're proceeding with that. It's a really important deal to both of us. I think the president is doing a review. We did a review when we came into government, so that makes good sense to me, because it's a really important... We're very long-time partners and allies and friends, and we've become friends in a short period of time.
2:27He's slightly more liberal than I am, to put it my... I will stand slightly on the left. For some reason, we make it worse. Mr. President, did you just say you should be giving away the barming of Israel? There's quite a few British voters who worry who side more with the Russians over the Ukraine war. Can you reassure British people that have not been there? You know what I said? Saving lives. I only care about saving lives. We have nothing to do with it except that Biden stupidly let us get into that mess and gave them$350 billion. dollars, 350 billion. And yet, despite that, you saw how we did in the Middle East.
3:04We took in 5.1 trillion dollars. We have 15 trillion dollars almost looking around that number, going to be invested in the U.S. So the money is not the thing in this case. It's 5 ,000 young people are being killed every week in Russia, Ukraine. And if I can stop that, I'll be very happy. They're Ukrainian and they're Russian. So you could say, what am I doing? But I'd like to see if I could stop. You said that Israel can fully eliminate the threat that Iran poses, this nuclear threat that they pose without the United States military help. Who said that? No, I'm asking if you believe they can without that.
3:40It's irrelevant. Something's going to happen. Have you spoken to the ledgerals? Do you consider traveling to the Mideast as part of any talks if it would help broker a deal of law? Yeah, but I think we're doing pretty well. We're talking. We have a thing called the telephone, so we're talking. But it's always better to talk in person. Mr. President, do you want to see a crazy inch in Iran? I want to see no nuclear weapon in Iran, and we're well on our way to making sure that happens. We had a discussion about that this morning. There's a G7 absolute clarity in relation to the nuclear program. We do not want to see it.
4:12Mr. President, do you have a response just about... What? Can you guarantee the UK will be protected from any future tariffs? The UK is very well protected. You know why? Because I like them. That's why. That's their ultimate protection. Thank you very much. The Prime Minister's done a great job. I want to just tell that to the people of the United Kingdom. He's done a very, very good job. He's done what other people, they've been talking about this deal for six years, right? Six years. And he's done what they haven't been able to do. So he's done really a very good job. What if he responds to Tucker Carlson criticizing you, saying that you were complicit in the war?
4:50I don't know what Tucker Carlson is saying. Let him go get a television network and say it so that people listen. And quickly, have you spoken to Zelensky before your bilats? Yeah, a lot of them. Japan? A lot of them. That was UK Prime Minister Keir Starmer and President Trump speaking at the G7 meeting in Canada, talking trade, Iran and Israel, Russia and Ukraine, and much more. Let's get straight to Megan Casella, who's got all the headlines from Canada. Megan. Absolutely, Melissa. That's not the first time we've seen the president on camera today. I had quite a few chances to see him. But it is the first time in the last few hours that we heard him there making some news, as you mentioned, on Israel and Iran, saying Iran is foolish not to sign a deal.
5:29He also said, and I quote here, Iran is basically at the negotiating table where they want to make a deal. And as soon as I leave here, we'll be doing something. Notable there, especially as markets were up today on hopes that there might be some ongoing negotiations and the Iranians might be coming to the negotiating table to strike some sort of an agreement. He's keeping that hope alive there. He also wasn't committing to sanctions on Russia. That's something that came up earlier today. A reporter asked if he'd be willing to put sanctions on Russia. At the time, he said it could happen. Today, just now, he was again noncommittal, saying sanctions cost us a lot of money.
6:04He didn't seem yet ready to be making that step. Then, finally, he also was saying that they had signed a trade agreement with the U.K. He was saying at the end there, a deal, negotiations that they've been working on for the past six years or so. And, Melissa, you'll remember this framework of a trade agreement, not a fully-fledged deal yet, but this framework was first announced in the Oval Office just about a month ago. It gave up a little bit on both sides, some market access for U.S. products like beef and ethanol, while the U.S. was keeping its baseline 10 percent tariff in place. In exchange, the U.K.
6:34could send some cars to the U.S. without as high of a tariff and was committing to buy some products to Boeing as well. That's what we expect they signed today, sort of formalizing that, because, remember, Keir Starmer, the prime minister, was not in the Oval Office for that. So advancing the ball a little bit further. Trade, of course, Melissa, being the backdrop to so many of these conversations today. And I'll flag just one last piece of news. It's just before this meeting that we saw with Starmer, the president also sat down with the president of the European Commission, Ursula von der Leyen, the White House says, at the EU's request.
7:05So that's, of course, a major deal we've been waiting for. We don't have a readout of that meeting just yet, but we can confirm that the two leaders did meet. Melissa? Megan, thank you. Megan Casella. And you are watching Fast Money. I'm Melissa Lee coming to you live from Studio B at the NASDAQ Market site. On the desk tonight, Tim Seymour, Karen Feinerman, Dan Nathan, and Guy Adami. Let's get to today's market rally. Stocks shaking off, escalating conflict in the Middle East. Concerns about the oil market, the ongoing terror threat to inch back toward record highs. Every single MAG7 stock in the green to kick off the week, but a handful of legacy tech names really stood out in the session.
7:38IBM, Microsoft both hitting all-time highs, and even Oracle, which pulled back slightly today, is still pacing for its best month in nearly three years. The move comes across the tech sphere, pushing the XLK ETF to its own record. So will it be these stocks that keep the markets rising even higher? We might even also have some positive news out of the G7 meeting when it comes to EU and the U.S. in a trade deal. Yeah, well, the math suggests it has to be. I would say 250, 300 S &P points a month ago. Tim said that the pain trade was higher and it's playing out in front of us. And in terms of these stocks, again, it sort of has to be these stocks that continue.
8:14It's just the names, which names sort of make sense. I think Oracle, which we've talked about for a while, I think right before our eyes, has gotten itself expensive. But IBM, if you look at the quarter they just put up and look at the valuation, look at the businesses they're getting into. Steve Grasso talks about quantum computing at 25 times next year's numbers, despite the move. I think IBM is the one that could catch people continually by surprise. So the Mag7, I think, you know, some of them I think of value stocks, even outside of the move they've had. I still think of them as somewhat in value territory.
8:43So I look at a name like Meta, the biggest position. I think it's protected from a lot of the issues that plague the rest of the market. And so I don't, you know, no tariffs. The balance sheet's in extraordinary shape. The margins are incredible. So I'm hanging with those. They're getting a little more expensive to me. The most expensive one is actually Netflix. That's the hardest one for me to hang on to. Yeah. I mean, we've sold upside calls. It hasn't worked. We've also been helped by this sort of re-ignition of the AI trade. Yeah, absolutely. NVIDIA CEO last week was all across Europe making partnership deals with a bunch of companies.
9:15I mean, there's a lot of buy-in that the AI trade is not over. I think that's right. I think we were reinvigorated by, you know, kind of the, call it the sovereign AI trade. We were reinvigorated by the reality that from NVIDIA's numbers, which came really well after the big move in the markets, We had a chance to really not only hear reaffirmation from NVIDIA, but we haven't heard anything different. In fact, the hyperscalers have kind of doubled down. We've had a couple of data center and kind of energy deals around AI energy demand. And we've heard from Constellation. We've heard from Microsoft.
9:46So, you know, I think that's all very important. And the market needs this leadership to go to all time highs. It doesn't mean you can't have a great market without the tech leadership. But I get back to and if you're doing relative kind of performance trades or doing those graphs at home, if you graph the the triple Q's by the SPY, you get to the high we were back in July, which is essentially point eight nine. We're right almost right there again, which would mean could you be getting relative leadership by the group that really takes you higher? The outperformance by semis from the low of markets from April 8th is about 23 percent to the S &P.
10:18That's all you need for markets to continue to move higher. doesn't mean that I think you don't think about all the things we think about every day in terms of where AI and deep seek and really post deep seek. The world's a different place. And yet it's not. It's notable, though, for the mag seven are still down in the year. Apple obviously trades very poorly. Google trades very poorly. Tesla trades very poorly on a relative basis. Right. And so they've come a long way. When Tim just mentions the ratio of the S &P relative to semis, you know, semis have doubled up the performance of the S &P 500 off the bottom.
10:47You know, the NASDAQ 100 is up about 32 percent. And I guess you've got to ask yourself, it's like, what's the ump? What's the thing? What is this not discounting, right? And so at this point, I mean, it's been a tremendous rally in such a short period of time. But, you know, if you look at a meta, here's a great example that everyone loves it. Karen loves it. And, you know, I look at this expectations, consensus expectations for earnings and sales growth are basically 13 percent. Right. And so I say to myself at 24, 25 times, it's really not that cheap. You said margins are beautiful. They are beautiful.
11:16They're 81 % or something like that. So I think that you have to make a bet that we're going to have earnings revisions higher for these groups. And you might. I mean, like, that's the thing. If you start to get these kind of return on investment and these use cases and all this stuff play out, I mean, I'm still a little skeptical that that's a 2025 thing. And maybe you see earnings revisions higher and maybe Meta does prove to be really cheap. Maybe Google gets by some of these headwinds and that is the cheapest one. I'm just not so certain right here. Well, for Meta, I think they are just spend, spend, spend right now.
11:47And this multiple is off of a run rate of spend, spend, spend. So if at some point they will slow down the relative spending, which I believe will happen, and the efficiency starts to come through, then I think that Meta will look very cheap here at some point in the future. Not that distant future. Yeah. Meta also had some news today that they're maybe finally monetizing WhatsApp somewhat more with it. You know, ads at least being displayed. I mean, there are so many different levers they seem to be able to pull, and they are definitely in the pull position in terms of the digital ad world. I think it's also notable that Google really quietly over the last month has maybe been the best performer of that group other than NVIDIA.
12:25And it gets back to, again, where I just think people got so negative on certain thematic elements of people have questioned the livelihood of some of the biggest companies in the world multiple times in the last three months. And I think that's proven to be wrong. We got to get to that. What is it, Karen? About 740 level in Facebook that we saw earlier this year, number one. Looks like it's going to get there. The efficiencies have been there, though. I'd say for the last four or five quarters from Facebook, you've heard how AI has helped them in terms of their margins. So they are getting the ROI in the back of it for sure.
12:56All right. Well, City's head of equity trading strategy recommends going long, high-quality stocks right now. Stuart Kaiser is behind the call. Stuart, great to have you with us. Nice to see you. Good to be here. We're talking about tech all-time highs once again, as if last week never happened, as if a trade war never happened, as if a conflict between Israel and Iran isn't happening right now. What do you make of this market move? I mean, I think the recovery today is just reassurance to the market that basically if oil doesn't dislocate to the upside, equity investors seem largely comfortable to kind of ignore some of the geopolitical risks.
13:28whether that's Russia and Ukraine, whether it's Israel and Iran. I mean, that was the case other than call it a couple weeks in March 2022 when he got oil up to like 120 bucks. Generally speaking, I think investors say that's the channel through which we're going to kind of handicap geopolitical risk. And since we didn't see that follow through today, markets kind of recovered. Vol came in and we're kind of back on the march higher. So how do you think about high quality stocks? What are those and what kind of environment are you bracing for? I think our view here is the setup for equity sounds a lot like it did at the beginning of the year, right?
13:59Which is earnings growth looks OK. Valuation is very high. Positioning looks quite long. You have attendant recession risks and a lot of headline risk as well. And in that environment, yeah, we want to be long U.S. equities, but we want to do it in a more conservative, high quality way. What's kind of changed for us is we like growth coming off the bottom. When you get those long end yields moving, the growth trade feels a little bit under threat. So we kind of rotated out of growth into quality as a result of what's going on in the interest rate market. Stuart, you mentioned positioning and length.
14:27I'm just trying to understand where your clients are. I mean, you're in the middle of the institutional world. You're talking to the biggest hedge funds in the world. You're talking to me. I get the sense that, if anything, they had really pulled back exposure. It wasn't the retail community that had changed a whole lot in terms of their MAGA view, but that there's no question that the directional, the longshore community. Any thoughts on that? Are they still, you know, underweight where they were six months ago? or do you think they actually have really turned it completely to for as long as they have been?
14:54Yeah, I think we'd probably put positioning 7 out of 10, probably a little less heavy than it was in late February, but significant, significant recovery in positioning. Long-short hedge funds, I think, got hurt a little bit in the initial 10 % drawdown, call it from mid-Feb to mid-March. They got their risk right, and I think we're actually able to play a little offense, you know, coming off the bottom. The second 10 % drawdown kind of got your macro-directional guys a little worse, so they've been kind of a little bit later to re-engage. So positioning is pretty full. It's probably not where we were in mid to late February, but it's not underweight.
15:25You're getting pretty close, getting pretty close. When you talk about real high quality companies and great balance sheets, where is energy? Where does that fit in? I thought that the move in energy down only a buck and change off the heels of what's been happening was pretty strong. Yeah, I mean, energy would not probably be right in the core of the quality stocks. There's probably a few that that would put you in there. I think what happened energy today is effectively. Yes, we didn't get the short term rip in oil, but it does seem like this risk is going to kind of be persistent and ongoing, and maybe the market's starting to assume maybe you'll get those longer-dated futures a little bit higher.
15:56Energy is definitely an under-owned part of the market, as you might imagine, structurally. So I think what you're also seeing there is a little bit of positioning kind of getting forced into the market, whether it's short covering or kind of right-sizing yourself, because, look, I mean, that's been a structural laggard for a while. So I think it's a little bit of positioning and a little bit of concern. This might kind of linger for a little bit in the market. The weaker dollar's been a tailwind. And at what point, though, has it become a concern? Because there's no bounce in the U.S. dollar.
16:20Yeah, I mean, it's concerning to the extent that it's volatile because it does kind of speak to this America U.S. exceptionalism is dead trade. Frankly, that trade was much more loud and vociferous until about March. And it's kind of calmed down. 1Q earnings, you know, really changed things for us. I think when hyperscalers, to your point, doubled down on this capex spend, it convinced institutions and I think foreign investors that they just they were underweight. The A.I. trade is as kind of comical as that sounds. And the bottom line is you can't have the AI trade on in the size and depth and liquidity you need without being in U.S.
16:52equities. Right. So I think that's kind of pushed people back in the market. So for now, with where the dollar is, I think you're OK. Investors, obviously foreign investors, it's a big impact for. And I think what you're seeing there is they're hedging a lot more of their dollar risk than they have in the past. So as long as we're under control, I think you're OK. But to your point, it is a headwind, particularly for foreign investment flows. Stuart, banks, BKX, has not really gotten as close to the highs as the S &P 500. KRE, regionals, don't act particularly well. And then if you look at all of these kind of whatever you want to call them, you know, Apollo, KKR, Blackstone, they actually do not trade well off the highs here and really off the lows, actually.
17:29What do you take from that price action in general? Look, I think banks were a little surprised at. You know, the deal calendar does actually look like it's picking up a little bit. You know, the circle IPO went pretty well. It looks like a little bit of regulatory relief. So banks trade is still something we like. On Friday, I think the stablecoin news coming out of the retailing side kind of put a little bit of pressure on fintech and some other parts of the market. So it could be that banks has been kind of a consensus long, so they're not getting sort of the incremental flows coming in. But, yeah, a little bit surprised, frankly, that that space hasn't performed better.
17:56We still do like the large-cap banks. Regional banks are a little tricky because that small-cap lower-quality trade is just really lacks sponsorship. So it's a little bit hard to like that. But larger-cap banks, it actually seems like a pretty good operating environment for them right now. Stuart, great to see you. Thank you. Thank you. Stuart Kaiser City. Do you feel better about the durability of these market levels here versus a week ago? No. I mean, I think the market's gotten more expensive, but it's been wrong to have that view. But in terms of valuation, not that that is a timing mechanism, but the market, once again, has gotten itself expensive.
18:27Just about any metric you want to look at, especially price-to-forward earnings in form of the S &P 500. Now, if earnings continue to surprise, which they have sort of, I guess, on the margins, then we had a different conversation. Maybe that multiple is warranted. I don't think so. All right. We've got a news alert with the details on the Senate tax bill. Emily Wilkins has got all the details here. Emily. Hey, Melissa. Yeah, the Senate just released their tax package. We can provide some updates on some of the things that we have been talking about here. Let's start with the clean energy tax credit.
18:58The Senate has extended a lot of the deadlines from what the House bill proposed, meaning that more projects, wind, solar, nuclear, are all going to be able to get those tax credits. Maybe not as many as in the original bill, but more than at least than was proposed in the House. We talked a little bit about the so-called revenge tax credit, or revenge tax rather, on foreign countries and foreign investors. The Senate has pared that one down a little bit, giving it a longer runway before it would go into effect. would only be 15 % rather than 20%. It does keep a lot of the proposals in the House bill that Trump has been pushing for, like no tax on tips, no tax on overtime.
19:40However, it does make those provisions a little more narrow, really focusing on those who are sort of low middle income and then capping the amount that can be deducted here. We are getting a lot more details on this bill. And of course, we'll be seeing how senators react when they come into town. One senator who might not be too happy is Rand Paul. He told us all that he just did not want to see that debt ceiling increase as a part of this bill. And a$5 trillion increase is included. Of course, Republicans wanting to get that done, make sure that they can do that without needing to negotiate with their Democratic counterparts.
20:13And then on SALT, which has really been a big sticking point today between the Senate and the House members. At this point, the Senate's just saying, hey, we're still negotiating on that. And so we'll see what they come up with in coming days. All right, Emily, keep us posted. Thank you, Emily Wilkins in Washington. Meantime today, we were watching shares of CoreWeave up more than 7 percent. This despite a downgrade from Bank of America. Adults putting a neutral rating on the stock due to valuation concerns. They did, though, raise the price target to 185 from 76, saying a new hyperscaler customer, an expanded contract with OpenAI, and a recent debt raise at a lower rate could keep the shares climbing.
20:47CoreWeave up nearly 300 percent since its IPO in March. Overall, though, the concern is that in order to fund this build out of data centers, It needs to keep borrowing. And those borrowing costs are getting higher and higher. They sold a bunch of debt in May at nine plus percent. And that's a lot. I just I don't know how you could think about fundamentals when there's something else structurally that's going on this that I think is the way bigger part, which is the short interest. Right. And that that manipulation, not calling it a manipulation in the SEC kind of sense, but that noise caused by that far outweighs anything, I think, on a valuation standpoint.
21:23Yeah, very clearly, this is a name that I've gotten wrong from the get-go, pre-IPO. It is one of those situations. It became a meme stock very quickly. I think a lot of that leverage that's on the balance sheet, some folks think it's something that they could take advantage of relative to the short interest, relative to the demand that they were supposedly sopping up. And they are sopping it up. And Microsoft obviously has been a huge customer at 70 % or so. I mean, at some point, NVIDIA is building data centers. Microsoft's going to get done building some data. They're all going to be competing with each other.
Read the full transcript
21:52and the story will fall apart. It's just not now. It's a meme stock. It just seems to me this is a case where a little bit of leverage is a dangerous thing. And it's unnecessary when there's other places to get pure exposure to the space. Coming up from Gears to Gucci, shares a caring surging as the fashion company poaches an auto exec to drive its turnaround plan. Will the CEO switch mean all green lights ahead for the lux retailer? And Meta going all out on advertising why the tech giant is monetizing WhatsApp for the first time and what it means for the staff. Back right after this.
22:31Welcome back to Fast Money. French fashion house carrying up 12 % today after announcing Luca DiMeo will take over as the CEO of the struggling luxury retailer. DiMeo just stepped down as CEO of French carmaker Renault and has worked in the auto sector for 30 years. He'll take over at Caring on September 15th. The company, which houses brands like Gucci, Saint Laurent and Balenciaga, has seen sales drop amid weaker demand. Shares are down 31 % in just the past year. It's an interesting pick. I mean, he's known as a brand builder, a marketer. He was in the auto industry currently. I know. So that is an interesting pick.
23:03I think the more interesting thing why the stock, maybe why the stock was up so much, is I think that Francois-Henri Pinot, whose father was, you know, the beginning of this, has not had a great run. To me, it started back when he decided to buy CAA, right? The distraction there. I don't know if you bought the whole thing or not, but just a tremendous distraction. And then Gucci, which is the main driver, the most important fashion house they have, has been a disaster, including their most recent hire wasn't really seen as particularly probably out of two out of the mainstream to be able to revitalize the brand.
23:37So the stock is down a lot. Is it cheap? No. There's a fair amount of debt as well. But I do think a change at the top is good. I'm still in Louis Vuitton. That has not been great at all. But I would rather be there at a similar valuation, maybe even a slightly better valuation than here. Because if I were the new CEO, I would come in, kitchen sink the thing. Oh, yeah. Right? For sure. So then maybe look to buy. Right. Guy, I know you have lots of thoughts about all the different fashion lines. I wear many of them. Et cetera. But in terms of the stock. $92 stock, I think, four years ago. You see where it's trading now.
24:12We traded the levels you probably saw in 2016. So that kitchen sink, maybe it's already happened in the price action of the stock over the last four years. But I'm with Karen on this one. But I do think despite the move today, you can take a flyer on the long side here. I just think luxury has been such a tough sell. And it's interesting. We thought maybe it was just limited to some of the beauty lines and the less luxury than these. In other words, the Altas and the Estee Lauders. But if you look at LVMH, I mean, we're near five-year lows. But, I mean, the valuation is very interesting. And it's, you know, it's a 6 % or 7 % free cash flow yield.
24:44I mean, the margins here are extraordinary. But, you know, this has been a bad trade that hasn't really shown the signs of bottoming yet. I think you have to be careful. And you have to wonder a little bit if the resale market is impacting these brands at all, now that it's so easy to buy used, gently used of all of these brands. Yes, true. But they've sort of helped make that so by increasing prices so dramatically during the pandemic. when everyone had money, they're not in the position to cut prices. They never want to do that. So they have to sort of stagnate and wait and not raise prices for a while, and that differential remains big.
25:20Would you buy something gently used from Guy Depp? What does gently used mean? I don't know. I think it's a contrasting term for you. Well, there's nothing gentle about me. That's exactly right. That's not true, actually. I do have my chance. You are on the inside. Coming up. Meta moving higher on news that is expanding its ad push to WhatsApp. All the details on what it means for the tech giant's competitive edge next, plus a biotech tumble shares of Surrepta Therapeutics getting slashed today. The headline that sent the stock dropping, what it means for the rest of the recently red-hot biotech space.
25:56You're watching Fast Money Live from the Nasdaq Market Site in Times Square. Back right after this.
26:08welcome back to fast money meta shares rising today on news that it will show ads in its whatsapp messaging platform the ads will live in a separate tab from users conversations the platform has more than three billion monthly active users shares of ad tech stocks like mag magnite pubmatic trade desk and tabula all rising sharply on the day dan you had some pretty sharp comments about this move? Well, it makes perfect sense. You have a platform that has three billion monthly active users. You might try to monetize it after 10 years of buying this company. I remember sitting on the desk the day that they announced it.
26:39I remember that. We were all like, what is WhatsApp? I knew what it was. I knew what it was. I travel internationally, but yeah, no, it was nobody knew. You know, listen, privacy was a thing. The founders wanted no ads, you know, end-to-end encryption, that sort of thing. Listen, if you're going to grow, you can't grow that many more people on the planet, right? They already have nearly half of them. You got to figure out ways to monetize the properties you have. I suspect it's going to be really good. You know, for them, I think it's for a user going to be really bad. When Tim travels internationally, maybe the slightly used things that he wears, he could put back, you know.
27:12Gently. Gently used. Yeah, I don't slightly use them, guys. Well, gently used. I would buy a gently used Tim Seymour, you know, so ex-Soviet Union to your days back then. Yeah. You know, the blazers that you wore. One of the blazers? Maybe some of those thin ties. Look, I'll go through my closet, guy. I can't wait. Off the rails here. Yeah, sorry. Well, Tim said that he travels internationally. I know, I understand that. But I mean, that's why he's an ambassador. This sounds great for Meta. This is a monetization channel that they have not explored yet. I think it is. And I do think it just shows.
27:45I mean, Meta, it's our world. It's their world, excuse me. And we just happen to be living in their ability to also dominate. If you're a small business and you're not dealing with Meta, you can't not deal with Meta. And I hear this constantly from various folks. So I think it's interesting. I'm not sure this is a game changer, but it's the kind of support to a stock that you say, hey, it's expensive. They're going to have something new tomorrow. They will. Karen, I agree. I mean, incrementally, it's nice. That's always been sort of part of the story. Maybe one day WhatsApp will find some monetization, whether subscription ads, whatever it might be.
28:16So I'm not against it, but it doesn't radically at this point change the story. Would you like to offer a trade guy or if you're just going to speak random things and I'm just going to know. I mean, my trade is, like I said earlier,$740, that prior high, I think in February, is in the crosshairs. We'll see what happens when you get there, but valuation is not a concern. By the way, that trade is somewhat gently used. Coming up, Sarepta Therapeutics cut in half. Shares sliding by more than 40%. The details behind the move, how the pharma and biotech space is holding up. Fast Money is back in two.
28:50Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money podcast. We're back right after this.
29:06Welcome back to Fast Money Stocks, rallying to start the week as investors digest the latest updates from the Israel-Iran conflict. The Dow jumping more than 300 points, the S &P up nearly 1%, and the tech-heavy Nasdaq leading the gains up 1.5%. Discount retailers continuing their climb, Dollar Tree, Dollar Gen, both higher today, adding to an impressive run over the past few months. Tim, you're commenting on this. I mean, they're being helped also by the bankruptcy of big lots, which is sort of clearing out and consolidating the space. Some consolidation of the space. But this was about a format that I think at one point late last summer, we were wondering whether it was going to survive, both because of the inflationary pressures that seemed structural and unable for them to – and then you layered on tariffs and whatnot.
29:45But we were already – remember, they were the first ones in whatever cyclicality we've had in terms of the economy, because I'm not even sure what cycle we're in when you talk about economic cycles. But certainly it looked like we were late cycle and it looked like the lower end consumer was suffering everywhere. These names are now back to essentially and these guys use this term a lot. We've almost backfilled those levels of where we fell off a cliff back in August. And it seemed again that the format was in trouble, let alone these names. One twenty five is that level Tim talks about in August where we dropped down, I think, almost down to 80 something.
30:18I think you can get back to$125, Jen. The thing I think about when I look at the strength of those two is Target and the problem there. Where is that share coming from? And I can't help but think it's coming from Target. Worth noting, Costco does not trade well. It closed very poorly today. It's down, I want to say, 5.5 % from those recent highs. Walmart also is kind of rolling over. So, again, we talk so much about the trade down and the fact that these guys are maybe catching some steam. I don't know. Maybe they're taking some share back. All right. So Serepta Therapeutics sinking 42 % today after the company reported a new death related to its Duchenne muscular dystrophy drug.
30:52This marks the second time a non-walking, non-ambulatory patient has died after developing acute liver failure. The company is suspending shipments of the gene therapy to non-ambulatory patients with no changes for patients with the ability to walk. The new setting shares to nine-year lows. For more on Serepta's path ahead, Mizuho Healthcare Strategist Jared Holes joins us here on set. Jared, great to have you with us. The management had a call this morning, and you were on that call. You talked to investors about the call. They highlighted the belief that they think that the ambulatory patient segment being treated with this drug could support profitability.
31:27But then there didn't seem to be real comfort in this event not happening in that group as well, right? I mean, the liver enzyme elevation happens in both. It doesn't seem to discriminate between non-ambulatory and ambulatory patients, which means that this acute liver failure could happen also in the other patient segment. Yeah, that's right. No one really knows. I mean, we've seen the first two cases have happened in this non-ambulatory setting. There probably are not enough patients that have been treated where we really have a sense of whether there's a greater than 0 % chance of this kind of bleeding into the other side of the population.
32:08So it's really a waiting game. I think what we're seeing around the street is what is the company worth if you remove the gene therapy completely from the model as though it were pulled or if the company decided to withdraw shipments completely. and I think investors and analysts are getting somewhere around$30 to$40 a share, depending. $30 or$40 a share, so it's a buy here? It might be a buy. I mean, these biotech blowups are typically buys when everyone sells on the day of the event. There's a lot of emotional transactions that you're seeing today. If the non-Exxon skipping franchise, which is the non-gene therapy franchise, as a billion dollars in revenue, and there's a pipeline, I think you can justify a higher price.
32:57It may not be much higher, but it might be higher than 20. This treatment was approved by Peter Marks at the FDA, and Peter Marks was basically ousted and then issued that letter that was so critical of the FDA. Is there fear that there's going to be additional blowback onto the company in some way that will make it more difficult for the company to climb out of this? It's certainly possible. I think some of the comments out of the new regime, the Macari and Prasad regime, and Prasad is the one who's replaced Peter Marks, that to me is a big variable. I mean, there could be a statement that, you know, that the FDA wants to make early on here, which would be to say, you know, pull the drug at least for the non-ambulatory patients and, you know, go from there.
33:40But I wouldn't be surprised at all based on what they've said about safety and efficacy of these drugs. And this has been approved on an accelerated fashion. So they could make Sarepta run an additional trial, see what those results look like, and then at a later stage approve it again. I think all of us have been waiting for the bounce to change gears in Novo Nordisk. Seemingly happened a couple weeks ago. Is it out of the woods or are we getting ahead of ourselves here? I don't think so. I mean, just too many variables at play here competitively with what Lilly's doing, all of the compounders, HIMS, et cetera.
34:12It was oversold. I think we all spoke about that. I'm not sure they're out of the woods. There's a lot competitively going on, and we've got to see how this market shakes out. When you get weekly scripts data and some analysts say, oh, the latest weekly scripts data indicate that it's further losing share to Eli Lilly, is that, I mean, does that still move the stock or is it assumed now? I mean, I'm just trying to figure out if it's still moving lower on this notion that it's losing out to Eli Lilly or if it's just moving lower on something else. Because if it's moving lower on the same news, that's very bad news for the stock.
34:40I think it really depends. I mean, we've seen a kind of plateau in a way, right? It's traded between 70 and 80 for the most part over the past month or two. And sometimes the script data moves it. Sometimes it does not. I think today that you had some additional headlines out of Lilly, you know, that they're offering more doses to direct to consumer. So I think it just really depends on the day. I'm not saying it doesn't matter, but I think it's situational. Jared, great to see you. Thank you. Thank you. Jared Hulse. Well, the Sarepta, I think he's right. If you strip out the concern today, they still have a billion-dollar drug that's getting seemingly no value.
35:16A lot of people pointed that out. I think Jared's right. I mean, these sell-offs are typically overdone, knee-jerk reactions that maybe take a day or two. But I think Sarepta is absolutely worth looking on the law side. And so as we look at biotech overall, whether it's XBI or IBV, XBI is outperformed. I just think that this is the environment, after also sentiment, that was as bad as it could get. And I guess it can always get worse. But I like the moves in the XLV. I like the moves in the XBI. And I think they can be bought in this environment. All right. We've got a news alert here on Warner Brothers Discovery, the media company drastically cutting compensation for CEO David Zaslav.
35:50His base salary will be cut from nearly$52 million last year to$3 million annually with his bonus opportunity reduced to$6 million. He will also receive almost 21 million stock options. The new contract will run through 2030. Shareholders voted earlier this month, remember, against Zaslav's pay package. That wasn't a binding vote, but it was a clear signal that they were very unhappy with the amount of pay he was getting relative to the stock performance or lack of performance, we should say. I really want to know what the terms of those 21 million stock options are. That's important, right? And we got that spin.
36:26I don't know exactly when that's taking place, but good. I mean, I'm glad the board heard the street. That was a pretty resounding thumbs down. Well, that's what Karen said that night. Hopefully the board is paying attention, and they clearly did. I mean, the only reason we brought it up that night, a couple weeks ago now, is because you never see anything like this. Typically, it's a rubber stamp. This time, it wasn't. All right. Coming up, we will dig into Lennar's results, the details and numbers from the quarter as soon as we get them. Plus, no need to conceal the move in Estee Lauder. The numbers out of China that are helping field today's jump and whether the beauty stock could see a makeover sometime soon.
36:59Details in Fast Money returns.
37:09Welcome back to Fast Money. Lennar on the move after reporting earnings. The numbers just crossing. Our Diana Olek has more on the homebuilders' results. Diana. Well, that's right, Melissa. Lennar's had some mixed results for Q2. It is reporting EPS of$1.81 per share versus estimates of$1.94. So that's light. But a beat on revenues at$8.38 billion versus estimates of$8.16 billion. Year over year, new orders increased 6 % and deliveries increased 2%, both within Lennar's guidance, but new orders slightly lower than the street's estimates. The average sales price of homes delivered was$389 ,000 in Q2.
37:44That compares with$426 ,000 in Q2 of last year. That decrease, according to the release, was primarily due to continued weakness in the market. Now, backlog is significantly lower than estimates, and the value of it is also lower. Lennar's chairman, Stuart Miller, said in the release, as mortgage interest rates remained higher and And consumer confidence continued to weaken. We drove volume with starts while incentivizing sales to enable affordability and help consumers to purchase homes. Still, gross margins of 17.8 % was in line with expectations. As for Q3 guidance, both new order and deliveries modestly below street expectations.
38:22Melissa, back to you. Diana, thank you. Diana Olek. So we do see weakness show up in the results, especially as they continue to buy down mortgages and offer other incentives. Which we've talked about average selling prices coming down across high end, low end. They're all seemingly coming down. They're talking about the weakness in the environment. Obviously, interest rates don't help. There are no bounce in these stocks. I mean, Paul Blenar, I think it traded down to maybe 98 on that low. Maybe we've bounced up to 110. But here we are now. I think these homebuilders, Blenar, Tull, DHI, can all continue to trade lower.
38:53Yeah. Look, on a trailing basis, you could say, wow, this looks really interesting relative to itself. But this is a case. I think the operating environment is very different. And that probably was really a rolling 18 months back. Things were almost as good as they got. And the chart tells you that. Guys, right, that 110 level takes you all the way back to what was the December 2021 highs. I think it forms a very important place the stock needs to hold. It's been grinding around there. I don't think you're trying to dip into this weakness yet. Yeah. I mean, how long can they keep buying down mortgages, right?
39:24I mean, the mortgage rates are really not budging. Right. And consumers are still on the sidelines. Plus, they're getting squeezed on other parts, right? Right. Right. So I don't know how long. I mean, this is a totally transformed industry. It's nowhere remotely close to what we saw, you know, 15 years ago or so. But, you know, it's not good for Home Depot and Lowe's, both of which I own. We want to see transactions. We want to see, you know, new projects. We did talk about that home equity loans that are increasing. That's helpful. We need way more than that. We need rates down. You know, if you see the market loosen up and you see buyers come in, you might have a real problem with this deportation stuff.
40:00I mean, like, if you think about it, like, workers are going to be hard to come by if you think the dependence on this industry. So, again, I just don't think it's such an easy trade here. And I think these guys are right. And Home Depot trades very poorly. Coming up, a mascara move from the mainland. Helping fuel Estee Lauder's surge. The China data pushing the cosmetic stock higher. And whether the beauty company could be a potential takeover target. That's next. More Fast Money in two.
40:31Welcome back to Fast Money. Yesterday, Lauder having its best day in over a year, rising almost 11 percent and closing at its highs of the session. The move coming on the back of stronger than expected retail sales data from China. The passing of Chairman Leonard Lauder over the weekend also sparking speculation the makeup giant could now put itself up for sale. Tim, I feel like was this in an acronym? So we point out, but I think there's never been a more important time to point out that being early is being wrong. and this was the E in Blysep, I think, in calendar year 23. I don't think this was even, maybe it was 24.
41:04But my view was that the worst of the China luxury trade was behind us and that Estee was also doing some very interesting things on Amazon with some of their core brands. I mean, they had distribution. They were what they were that we were seeing, cosmetic and beauty as a segment, hold up, and I thought it was time. It wasn't time, and the stock traded a lot lower, but the China strength here is important. I think some of the change at the company, the sense that there was stuck in some of its ways and that I think you've had a lot of the family that have dominated this company for a long time.
41:34I think today's move was probably more ceremonial than anything. I think it probably was related to the China news. The stock now through the 200 day. That's interesting. It is interesting because, in fact, it's been below that. And this is a pretty significant breakout. So I'm not sure the fundamentals have changed so much today. But I do think that the stock has been looking for a base and a breakout for a long time. When a family is involved, you have to wonder how much control this family still has. A lot, it seems, as we were looking. So it sounds like, you know, people wonder, oh, is any part of this, well, maybe it'd be up for sale.
42:04It is not up for sale unless the family wants it up for sale, which at the moment I don't think is the case. There has been a fair amount of turmoil in the last couple of years in the C-suite, in the boardroom. I think there are several lauders on the board now. I don't believe Leonard was one of them. Up next, final trades.
42:29Final trade time, Tim. In case the folks don't want to know, Guy and I on the commercial break, we're just talking about how Karen Carpenter is very underrated. I don't think anybody was happy. A &D, though, I think also underrated in the semi-space. Karen? I am going to dig, and Guy suggests, dig down and look into carrying more closely. Falling a long way. Dan. Yeah, here's a bit contrarian. The dollar UUP ETF to play at double bottom at 27. The haunting vocals of Karen Carpenter and the great drumming, one of the top five drummers of all time. Can you sing a verse for us? I would if we had more time.
43:04Fleetport Mac Moran, Mel. Promises, promises. Thanks for watching Fast Money. Mad Money. Jim Cramer starts right now.
43:18of CNBC, NBCUniversal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such. To view the full Fast Money Disclaimer, please visit cnbc.com forward slash Fast Money Disclaimer.
From the publisher
Stocks kicking off the week in the green, as investors digest the latest from the Israel-Iran conflict. The names seeing the biggest moves, and if it will be the Mag7 or Legacy tech stocks that lead the market higher. Plus A biotech beatdown, as shares of Sarepta Therapeutics get hit. The headlines hitting that name, and where one top healthcare analyst sees the biotech and pharma space heading next.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.
